Kazia Therapeutics Limited ADR (KZIA): Insights At A Glance

After grabbing 11639.0 shares, the institutional investor is now in possession of 11639.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.04% having worth around $5121.0. Moreover, BNP Paribas Financial Markets increased its share by 5202.0 to have a control over 8500.0 shares. And McGlone Suttner Wealth Management raised its holdings to 85.0 shares by acquiring 85.0 shares or 0.00% of the stake.

Kazia Therapeutics Limited ADR (KZIA) concluded trading on Thursday at a closing price of $0.37, with 2.6 million shares of worth about $0.96 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -57.03% during that period and on Thursday, January 25 the price saw a gain of about 5.57%. Currently the company’s common shares owned by public are about 23.63M shares, out of which, 23.62M shares are available for trading.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The company recently came buying 0.0 shares which brought its stake up to 0.02% of the company’s outstanding shares.

Stock saw a price change of 10.13% in past 5 days and over the past one month there was a price change of -9.70%. Year-to-date (YTD), KZIA shares are showing a performance of -15.93% which decreased to -62.68% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.30 but also hit the highest price of $1.68 during that period. The average intraday trading volume for Kazia Therapeutics Limited ADR shares is 122.86K. The stock is currently trading -2.91% below its 20-day simple moving average (SMA20), while that difference is down -23.00% for SMA50 and it goes to -58.86% lower than SMA200.

Virtu Americas LLC acquired 11639.0 shares of Kazia Therapeutics Limited ADR having value of about $5121.0. Kazia Therapeutics Limited ADR (NASDAQ: KZIA) currently have 23.63M outstanding shares and institutions hold larger chunk of about 1.00% of that. Holding of mutual funds in the company is about 0.02% while other institutional holders and individual stake holders have control over 0.82% and — of the stake respectively.

The stock has a current market capitalization of $8.73M and its 3Y-monthly beta is at 2.15. It has posted earnings per share of -$0.83 in the same period. It has Quick Ratio of 1.42 while making debt-to-equity ratio of 0.15. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for KZIA, volatility over the week remained 17.43% while standing at 17.67% over the month.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Maxim Group on October 14, 2021 offering a Buy rating for the stock and assigned a target price of $18 to it.

Most Popular

Related Posts